Theranos Lab Ban Imposed By U.S. Regulator

Elizabeth Holmes, TheranosElizabeth Holmes

Theranos Inc. founder Elizabeth Holmes has been banned from maintaining a blood-testing laboratory for at least two years.

U.S. Federal health regulators imposed the ban while also withdrawing approval for the Theranos lab in California. The sanctions were imposed by the Centers for Medicare and Medicaid Services, and were confirmed by the company in a press release published late Thursday, writes Michael Siconolfi for The Wall Street Journal.

Sanctions handed down to one-time technology darling

Other sanctions include a monetary penalty, the amount of which has yet to be confirmed. Theranos had looked set to revolutionize blood testing, but has come under massive scrutiny since The Wall Street Journal questioned the technology behind the company in an article published last October.

Theranos promises that it can carry out a wide range of blood tests using just a few drops of blood. However scientists have expressed their doubts on the effectiveness of the technology. Theranos was valued at $9 billion in 2014 and shot to prominence as part of the tech boom before the story began to unravel.

“We accept full responsibility for the issues at our laboratory in Newark, California, and have already worked to undertake comprehensive remedial actions. Those actions include shutting down and subsequently rebuilding the Newark lab from the ground up, rebuilding quality systems, adding highly experienced leadership, personnel and experts, and implementing enhanced quality and training procedures,” Ms. Holmes said in a statement.

Theranos in choppy waters

“While we are disappointed by CMS’ decision, we take these matters very seriously and are committed to fully resolving all outstanding issues with CMS and to demonstrating our dedication to the highest standards of quality and compliance,” Ms. Holmes said.

Under the terms of the sanctions the California laboratory will no longer be able to receive Medicare and Medicaid payments for its services. The company said it plans to work with CMS to “resolve and remediate outstanding issues in the Newark lab, and will continue to provide services to its customers through its Arizona lab.”

Other issues for Theranos include the recent loss of Walgreen Co. as a major retail partner.

There is a chance that the company could appeal the decision, which would at least delay some of the sanctions. That could mean that the lab would still have its license until the appeals process was completed. The process could take months to complete and appeals are rarely successful.

For exclusive info on hedge funds and the latest news from value investing world at only a few dollars a month check out ValueWalk Premium right here.

Multiple people interested? Check out our new corporate plan right here (We are currently offering a major discount)



About the Author

Brendan Byrne
While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. To contact Brendan or give him an exclusive, please contact him at theflask@gmail.com

Be the first to comment on "Theranos Lab Ban Imposed By U.S. Regulator"

Leave a comment

Your email address will not be published.